June 25, 2019
Patent “thicketing” occurs when a brand-name pharmaceutical company accumulates dozens of patents near the end of the product lifecycle under the guise of “innovative” processes or development that warrant additional protections
June 25, 2019
The Association for Accessible Medicines (AAM) Biosimilars Council found that delayed entry of biosimilars due to patenting has cost the U.S. health care system an astounding $7.6 billion in lost savings since 2015.
benefit of biosimilars
June 24, 2019
Dr. Sameer Awsare sat down with the Biosimilars Council to talk about biosimilars, their benefits and the hurdles to adoption in the United States. Watch the interview to hear his informed perspective.
June 11, 2019
This summer, as part of our commitment to broad stakeholder education about the promise of biosimilars, the Biosimilars Council will launch the first in a series of “member spotlights” – in-depth content featuring experts from our member companies sharing their unique experience and perspective on timely issues impacting the emerging biosimilars marketplace.
June 11, 2019
We’re thrilled to kick our Spotlight Series off this month with Dr. Hillel Cohen, Executive Director of Scientific Affairs for Sandoz.
June 7, 2019
Biosimilars are a competitive, effective alternative for U.S. patients prescribed brand biologic treatments, however despite over ten years of approvals, the U.S. has not yet realized the full potential of biosimilars. While we continue to see additional approvals, it has become clear that obtaining approval for a biosimilar is only the first of many important steps to ensure market adoption.

Want to keep up to date with the biosimilars industry?

Sign up for Biosimilars Council Newsletter to hear about the field, learn about events, and find out how you can make an impact.